MDXH Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	26 967.00
Average Volume	71 966.00
Market Cap	67.40M
EPS	$0 ( 2024-03-06 )
Next earnings date	( $-0.300 ) 2024-06-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.180
ATR14	$0.0230 (0.93%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-03	Mvm Partners, Llc	Buy	1 000 000	Common Stock
2021-11-04	Mvm Partners Llp	Buy	0	Common Stock

INSIDER POWER
100.00
Last 1 transactions
Buy: 1 000 000 \| Sell: 0

Volume Correlation

Long: 0.22 (neutral)

Short: 0.83 (strong)

Signal:(47.563) Same movement expected

MDxHealth SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MDxHealth SA Correlation - Currency/Commodity

-0.18
( neutral )

-0.51
( weak negative )

0.00
( neutral )

0.12
( neutral )

-0.11
( neutral )

MDxHealth SA Financials

Annual	2023
Revenue:	$70.19M
Gross Profit:	$39.44M (56.18 %)
EPS:	$-1.660

FY	2023
Revenue:	$70.19M
Gross Profit:	$39.44M (56.18 %)
EPS:	$-1.660

FY	2022
Revenue:	$37.05M
Gross Profit:	$19.22M (51.87 %)
EPS:	$-3.16

FY	2021
Revenue:	$22.24M
Gross Profit:	$10.41M (46.82 %)
EPS:	$-2.40

Financial Reports:

No articles found.

MDxHealth SA

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.